Virtual Tour


Episode 5 – On Demand

The FAST™ System has the Potential to Expedite ID & AST for Bloodborne Pathogens from Positive Blood Cultures
David Pride, MD, PhD, Infectious Disease Specialist, UC San Diego Health

Episode 4 – On Demand

Impact of reducing time to results in septic patient management
Dr. David Haake, Chief Medical Officer, Qvella

Episode 3 – On Demand

Saving time in microbiological blood culture diagnostics
Prof. Dr. med. Alexander Dalpke (TU Dresden)

Episode 2 – On Demand

Reduce time from PBC to actionable results by generating a Liquid Colony™
Herbert Torfs, PhD, V.P. of Business Development EMEA, Qvella and Professor Alexia Verroken, MD, PhD, Clinical Microbiologist, Saint-Luc University Hospital

Episode 1 – On Demand

A New Paradigm in Positive Blood Culture Processing
Susan Novak-Weekley, PhD, D(ABMM), S(M) ASCP
Vice President of Medical Affairs, Qvella


Evaluation of a Novel Sample Preparation Method for Rapid Antimicrobial Resistance Testing Directly from Positive Blood Cultures.


Comparison of a Novel Sample Preparation Method for Positive Blood Cultures vs. Standard of Care Overnight Sub-Culture: 0.5 McFarland Cell Concentrations and Antimicrobial Susceptibility Test Results.


A Novel Sample Preparation Method for Positive Blood Cultures: Assessment of Sample Stability for Downstream Identification and Antimicrobial Susceptibility Testing.

San Diego

Analysis of the FAST™ System for expedited identification and susceptibilities of bloodborne pathogens.


Performances of the FAST™ System enabling speeded-up positive blood culture ID/AST results using Bruker MALDI-TOF MS< BD Phoenix and disk diffusion.


Evaluation of the FAST™ System: an automated and rapid system for isolating microbial cells from positive blood culture.


Evaluation of the FAST™ System (Qvella) for accelerated species identification and antimicrobial susceptibility testing from positive blood culture bottles using the Bruker MALDI and bioMerieux Vitek 2.

FAST™ System and FAST PBC Prep Cartridge have received CE marking for in-vitro diagnostic (IVD) use in Europe (as per EU IVDR 2017/746) and are now listed as Class I IVD devices with the US FDA.

These devices have not been validated for any downstream diagnostic applications and are only indicated for positive blood culture specimens containing bacteria.